Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Ginkel

Cardiovascular Disease Santa Maria, CA Medical Doctor

NPI 1649272766 CMS profile 74792

220 S Palisade Dr, Suite # 101, Santa Maria, CA 93454

Open in the dashboard

General payments

$7,609

370 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Ginkel of Santa Maria, CA is reported in the CMS Open Payments database as having received $7,609 across 370 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $930 40
2024 General $1,080 48
2023 General $1,223 53
2022 General $1,328 64
2021 General $1,264 54
2020 General $711 40
2019 General $1,074 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Ginkel
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Mark Ginkel were reported at $930. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Mark Ginkel Cardiovascular Disease median Middle half National median
2019 $1,074 $450 $127–$1,392 $163
2020 $711 $242 $77–$751 $114
2021 $1,264 $335 $101–$1,037 $132
2022 $1,328 $395 $121–$1,211 $149
2023 $1,223 $443 $136–$1,283 $160
2024 $1,080 $450 $136–$1,323 $164
2025 $930 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biosense Webster, Inc. $1,805 69 payments
  2. Amgen Inc. $1,190 80 payments
  3. Pfizer Inc. $632 39 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $486 23 payments
  5. Novartis Pharmaceuticals Corporation $471 23 payments
  6. Janssen Pharmaceuticals, Inc $455 30 payments
  7. Merck Sharp & Dohme Corporation $448 21 payments
  8. Abbott Laboratories $446 8 payments
  9. Medtronic, Inc. $303 10 payments
  10. AstraZeneca Pharmaceuticals LP $297 14 payments
  11. Other $1,074 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,410 367 payments
  2. Debt forgiveness $131 1 payment
  3. Education $68 2 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $1,596 63 payments
  2. Repatha $1,190 80 payments
  3. VERQUVO $502 23 payments
  4. ELIQUIS $489 26 payments
  5. LifeVest $486 23 payments
  6. XARELTO $455 30 payments
  7. ENTRESTO $224 12 payments
  8. VYNDAQEL $218 18 payments
  9. LEQVIO $212 9 payments
  10. Corlanor $200 15 payments
  11. Other $2,356 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

5,371

Median for Cardiology: 2,533

Drug cost

$1,257,609

Median for Cardiology: $485,213

Branded share of claims

24.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 586 $661,053
Xarelto Rivaroxaban Brand 167 $229,262
Entresto Sacubitril/Valsartan Brand 91 $133,376
Repatha Sureclick Evolocumab Brand 62 $92,572
Praluent Pen Alirocumab Brand 37 $38,334
Farxiga Dapagliflozin Propanediol Brand 22 $24,734
Rosuvastatin Calcium Generic 525 $12,097
Ezetimibe Generic 333 $11,500
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 24 $9,089
Metoprolol Succinate Generic 508 $7,492

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$419,915

Medicare's payments for the services billed

Medicare patients

1,443

Average age 77

Services billed

5,044

682 women, 761 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 40%
Atrial fibrillation 39%
Diabetes 36%
Chronic kidney disease 35%
Heart failure 25%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $86
$86 586 —
VYNDAQEL
  • PFIZER INC. $83
$83 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $71
$71 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $70
$70 — —
Repatha
  • Amgen Inc. $37
$37 62 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

370 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record